Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2 while the page continues to show a 403 Forbidden error.
    Difference
    0.3%
    Check dated 2026-10-17T14:39:02.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The footer revision number changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.3%
    Check dated 2026-10-10T14:36:10.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    29 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the expected study content and indicating the page is currently inaccessible.
    Difference
    20%
    Check dated 2026-09-19T19:12:26.000Z thumbnail image
  5. Check
    50 days ago
    Change Detected
    Summary
    The NIH funding note 2016 ( U.S. NIH Grant/Contract ) was added to the study metadata, and the page revision was updated to v3.6.6 (replacing v3.6.5).
    Difference
    0.1%
    Check dated 2026-08-29T19:10:24.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The page now displays the full study record for NCT03222856, replacing the prior error page and including the study overview, eligibility criteria, and locations.
    Difference
    64%
    Check dated 2026-08-15T15:12:05.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.6.5 instead of Revision: v3.6.4, reflecting a small version update.
    Difference
    0.0%
    Check dated 2026-08-08T10:48:54.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.